Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib plus lenalidomide maintenance in highly aggressive B-cell lymphoma
ChiCTR2600135230Phase 4Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of orelabrutinib and lenalidomide in large-cell lymphoma and diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Duration of complete remission (CR + CRi). Started Mar 2021; status: completed.
02
Drugs
orelabrutiniblenalidomide
03
Conditions
large-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2600135230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135230.